Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study
Journal
Gynecologic Oncology
Journal Volume
134
Journal Issue
3
Pages
516-522
Date Issued
2014
Author(s)
Hsu K.-F.
Chou H.-H.
Huang C.-Y.
Fu H.-C.
Chiang A.-J.
Tsai H.-W.
Chen J.-R.
Ke Y.-M.
Chang C.-C.
Chen T.-H.
Lin S.-H.
Ho C.-M.
Abstract
Objective The aim of this study was to investigate the clinical and pathological characteristics of uterine clear cell carcinoma (UCCC) and the treatment of this disease in relation to patient outcomes. Methods The clinicopathological data for and the management of all patients with UCCC who presented between 1991 and 2010 at 11 member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) were retrospectively reviewed. Results There were no significant differences in 5-year overall survival (OS) rates between patients with pure UCCC (n = 100) and non-pure UCCC (n = 53) at the same surgical stage, with OS rates of 92.6%, and 87.7% for stage I; 83.3% and 83.3% for stage II; 64.0% and 67.8% for stage III; and 16.7% and 0% for stage IV (n = 1), respectively. Tumor stage and age independently influenced the OS rate of UCCC. For the patients with early stage UCCC, the adjuvant therapy modality was the only significant prognostic factor for recurrence-free survival. The patients with early stage UCCC who received adjuvant therapy had excellent 5-year recurrence-free survival and OS rates compared to those who received radiotherapy (100% vs. 74%, p = 0.01; 100% vs. 72%, p = 0.03). Conclusions The 5-year survival rates of patients with pure UCCC and non-pure UCCC were similar. The prognosis for surgical staging of patients with stage I/II UCCC was encouraging. Postoperative adjuvant platinum-based chemotherapy is recommended for patients with early stage UCCC who are at a high risk of recurrence. ? 2014 Elsevier Inc.
SDGs
Other Subjects
cyclophosphamide; doxorubicin; epirubicin; ifosfamide; paclitaxel; adjuvant radiotherapy; adult; age; aged; Article; brachytherapy; cancer adjuvant therapy; cancer prognosis; cancer recurrence; cancer size; cancer staging; cancer survival; clear cell carcinoma; distant metastasis; female; follow up; human; major clinical study; overall survival; paraaortic lymph node; postoperative care; priority journal; progression free survival; recurrence free survival; retrospective study; treatment outcome; uterus carcinoma; adenocarcinoma; adjuvant therapy; article; clear cell carcinoma; middle aged; mortality; multicenter study; pathology; prognosis; survival rate; Taiwan; uterus cancer; very elderly; Adjuvant therapy; Clear cell carcinoma; Uterine cancer; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Taiwan; Treatment Outcome; Uterine Neoplasms
Type
journal article